Windtree Therapeutics, Inc. Debt/Equity

Debt/Equity of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2020 was 0.25 (a -14.09% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -42.18%
  • Annual Debt/Equity for 2019 was 0.26 (a -21.79% decrease from previous year)
  • Annual Debt/Equity for 2018 was 0.34 (a -153.79% decrease from previous year)
  • Annual Debt/Equity for 2017 was -0.63 (a -27.69% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Windtree Therapeutics, Inc.

Most recent Debt/Equityof WINT including historical data for past 10 years.

Interactive Chart of Debt/Equity of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.25 0.29
2019 0.26 0.43 0.4 0.36 0.26
2018 0.34 -0.65 -0.62 -0.62 0.34
2017 -0.63 -0.74 -0.78 -0.97 -0.63
2016 -0.87 -1.09 -1.64 -5.02 -0.87
2015 3.02 1.4 -6.98 2.68 3.02
2014 1.06 0.69 0.49 0.39 1.06
2013 0.32 1.18 0.38 0.66 0.32
2012 0.01 0.01 0.01 0.01 0.01
2011 0.23 0.07 0.04 0.02 0.23
2010 0.07 0.05 0.26 0.9 0.07

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.